Department of Biochemistry, Maulana Azad Medical College and Associated Hospitals, New Delhi-110002, India.
Prince Fahd Bin Sultan Research Chair, Faculty of Applied Medical Sciences, University of Tabuk, Tabuk, Saudi Arabia.
Microrna. 2020;9(1):49-57. doi: 10.2174/2211536608666190225111234.
Epithelial ovarian cancer continues to be a deleterious threat to women as it is asymptomatic and is typically detected in advanced stages. Cogent non-invasive biomarkers are therefore needed which are effective in apprehending the disease in early stages. Recently, miRNA deregulation has shown a promising magnitude in ovarian cancer tumorigenesis. miRNA-145(miR- 145) is beginning to be understood for its possible role in cancer development and progression. In this study, we identified the clinicopathological hallmarks altered owing to the downexpression of serum miR-145 in EOC.
70 serum samples from histopathologically confirmed EOC patients and 70 controls were collected. Total RNA from serum was isolated by Trizol method, polyadenylated and reverse transcribed into cDNA. Expression level of miR-145 was detected by miRNA qRT-PCR using RNU6B snRNA as reference.
The alliance of miR-145 profiling amongst patients and controls established itself to be conspicuous with a significant p-value (p<0.0001). A positive conglomeration (p=0.04) of miR-145 profiling was manifested with histopathological grade. Receiver Operating Characteristic (ROC) curve highlights the diagnostic potential and makes it imminent with a robust Area Under the curve (AUC). A positive correlation with the ROC curve was also noted for histological grade, FIGO stage, distant metastasis, lymph node status and survival.
Our results propose that miR-145 down-regulation might be a possible touchstone for disease progression and be identified as a diagnostic marker and predict disease outcome in EOC patients.
上皮性卵巢癌仍然是对女性的严重威胁，因为它无症状，通常在晚期才被发现。因此，需要有强有力的非侵入性生物标志物，以便在早期阶段有效地发现疾病。最近，miRNA 的失调在卵巢癌的肿瘤发生中显示出了有希望的程度。miR-145（miR-145）开始因其在癌症发展和进展中的可能作用而被理解。在本研究中，我们确定了由于血清中 miR-145 的下调而改变的临床病理特征在卵巢癌中。
收集了 70 例经组织病理学证实的卵巢癌患者和 70 例对照者的血清样本。采用 Trizol 法从血清中分离总 RNA，多聚腺苷酸化并反转录为 cDNA。使用 RNU6B snRNA 作为参照，通过 miRNA qRT-PCR 检测 miR-145 的表达水平。
患者和对照组之间的 miR-145 谱分析的联合结果具有显著的 p 值（p<0.0001）。miR-145 谱分析与组织病理学分级呈正相关（p=0.04）。受试者工作特征（ROC）曲线突出了诊断潜力，并使其具有稳健的曲线下面积（AUC）。ROC 曲线也与组织学分级、FIGO 分期、远处转移、淋巴结状态和生存呈正相关。
我们的研究结果表明，miR-145 的下调可能是疾病进展的一个可能标志，并可以作为卵巢癌患者的诊断标志物和预测疾病结局的指标。
